Aim: To compare serum levels of angiogenesis-related factors between 14 women with HELLP (hemolysis, elevated liver enzymes and low platelet count) syndrome and a woman with acute fatty liver of pregnancy (AFLP). Methods: Serum samples were collected in 2004-2008 and 2013-2016. The levels of soluble fms-like tyrosine kinase 1 (sFlt-1) and placental growth factor (PlGF) were measured by an automated electrochemiluminescence immunoassay using Elecsys sFlt-1 and Elecsys PlGF. After logarithmic transformation, levels of sFlt-1, PlGF and the sFlt-1/PlGF ratio in a woman with AFLP were compared with those in women with HELLP syndrome, using the one-sample t-test. Results: At 37 weeks of gestation, a patient was diagnosed with AFLP based on Swansea criteria (showing six features including elevated transaminases), and she also showed a duodenal ulcer with active bleeding, thrombocytopenia and hypertension. Her serum levels of sFlt-1 and sFlt-1/PlGF ratio were significantly higher than in those with HELLP syndrome (273 040 pg/mL vs 15 135 [mean], P < 0.001; 4236 vs 224, P < 0.001; respectively). However, her serum level of PlGF was not significantly different from those with HELLP syndrome. Conclusion: Serum levels of sFlt-1 and the sFlt-1/PlGF ratio, but not PlGF, in a woman with AFLP were markedly higher than those in women with HELLP syndrome. AFLP may be a different clinical entity from HELLP syndrome based on angiogenesis-related factors. Clinically, the sFlt-1/PlGF ratio may be used to rapidly distinguish AFLP from HELLP syndrome. Key words: acute fatty liver of pregnancy, duodenal ulcer, hemolysis, elevated liver enzymes and low platelet count syndrome, placental growth factor, reference range, soluble fms-like tyrosine kinase 1.
Introduction
Acute fatty liver of pregnancy (AFLP) is a relatively rare obstetric emergency involving liver dysfunction. 1, 2 The survival of both the mother and baby may be at risk if early recognition and appropriate management are not performed. 3, 4 Although both AFLP and HELLP (hemolysis, elevated liver enzymes and low platelet count) syndrome patient show abnormal liver function test results, such as increased aspartate transaminase (AST) and/or increased alanine transaminase (ALT), the finding of reduced hepatic metabolic activity could not distinguish the two diseases. Clinical diagnostic criteria for the diagnosis of AFLP (Swansea criteria) have been proposed. 5 As HELLP syndrome is diagnosed when elevated AST, a low platelet count and increased lactate dehydrogenase (LDH) are observed simultaneously, 6 AFLP is often complicated by HELLP syndrome. However, concerning the severity of AFLP based on the abovementioned diagnostic criteria, clinical features of AFLP are more severe than those of HELLP syndrome. 7 In most AFLP patients, a prolonged prothrombin time, elevated serum creatinine and uric acid levels, elevated total bilirubin concentrations and leukocytosis are observed. 3, 7 In addition, pregnancyinduced antithrombin deficiency (PIATD) can be useful for the early diagnosis of AFLP, 8 although PIATD is not included in the Swansea criteria. In women with AFLP, antithrombin (AT) activity is exclusively and markedly depressed, ranging from 0.0% to 69%, 8 while AT deficiency in women with HELLP syndrome is relatively mild (mean AT activity in the diagnosis of HELLP syndrome: 60% [range 18-98%]; mean AT activity at delivery: 56% [range 18-95%]). 9 Gestational hypertension and/or pre-eclampsia is often accompanied by AFLP (26-70%) and HELLP syndrome (80-100%). 8 Recently, it was reported that there are abnormal angiogenesis-related factor levels in maternal circulation, such as increased soluble fmslike tyrosine kinase 1 (sFlt-1), decreased placental growth factor (PlGF), increased sFlt-1/PlGF ratio and increased soluble endoglin, observed in both women with pre-eclampsia and those with HELLP syndrome. [10] [11] [12] [13] [14] [15] [16] However, to our best knowledge, there have been no reports on angiogenesis-related factor levels in women with AFLP.
In this study, we compared serum levels of sFlt-1, PlGF and the sFlt-1/PlGF ratio in 14 women with HELLP syndrome and a woman with AFLP. Since AFLP patients usually have severer conditions than HELLP syndrome patients, we hypothesized that the serum levels of sFlt-1 and the sFlt-1/PlGF ratio in the woman with AFLP would be markedly higher than those in women with HELLP syndrome: this study was conducted to test this hypothesis.
Methods

Subjects and procedures
In 2004-2008 (Rin-03-01) and 2012-2016 (I-12-78), two different prospective cohort studies were planned to evaluate the circulating levels of sFlt-1, PlGF and the sFlt-1/PlGF ratio in women with gestational hypertension, gestational proteinuria and pre-eclampsia. In 2009, we also constructed the reference ranges of serum levels of the sFlt-1/PlGF ratio, using the data collected in the Rin-03-01 study, with a fund for contract research from Roche Diagnostics K. K. (Rin-09-02). 17 All three studies were approved by the Ethics Committee of Jichi Medical University. In the Rin-03-01 and I-12-78 study, 3 and 11 pregnant women with HELLP syndrome gave written informed consent, respectively. In addition, in the I-12-78 study, a pregnant woman with AFLP gave written informed consent.
Measurement of sFlt-1, PlGF and the sFlt-1/PlGF ratio A volume of 5 mL of blood samples were collected into plain tubes, centrifuged at 4 C and 2500 rpm for 15 min and stored at −20 C until use. The automated electrochemiluminescence immunoassay (ECLIA) of sFlt-1 and PlGF using Elecsys sFlt-1 (Roche Diagnostics) and Elecsys PlGF (Roche Diagnostics) were performed using Modular Analytics E 170 (Roche Diagnostics) according to the manufacturer's instructions, in the laboratory of Roche Diagnostics Japan.
Definition of high sFlt-1, low PlGF and high sFlt-1/PlGF ratio using serum in pregnant women at 19-38 weeks of gestation
We recently established normal reference ranges of serum levels of sFlt-1, PlGF and the sFlt-1/PlGF ratio in pregnant women at 19-38 weeks of gestation. 17 A high sFlt-1 was defined as a level of sFlt-1 equal to or higher than the 95th percentile curve of gestationalage-specific normal reference ranges of serum sFlt-1 levels; a low PlGF was defined as a level of PlGF lower than the 5th percentile curve of gestational-agespecific normal reference ranges of serum PlGF levels; and a high sFlt-1/PlGF ratio was defined as a ratio equal to or higher than the 95th percentile curve of gestational-age-specific normal reference ranges of the serum sFlt-1/PlGF ratio. 17 Definition of HELLP syndrome and AFLP HELLP syndrome is diagnosed when elevated AST (normal reference range: 11-30 U/L), a low platelet count (normal reference range: ≥150 000/μL) and increased LDH (normal reference range: 109-216 U/L) are observed simultaneously. 6 Clinical diagnostic criteria for the diagnosis of AFLP (Swansea criteria) have been proposed. 5 When six or more of the following features in the absence of other hepatic diseases: vomiting, abdominal pain, polydipsia/polyuria, encephalopathy, elevated bilirubin, hypoglycemia, elevated urate, leukocytosis, ascites, elevated transaminases, elevated ammonia, renal impairment, coagulopathy and microvesicular steatosis on biopsy, were observed during pregnancy or the puerperal period, the woman was diagnosed with AFLP. A small-forgestational-age (SGA) infant was defined as an infant with a birth weight less than the 10th percentile for the Japanese population. 18 
Statistics
Continuous data are presented as the mean AEstandard deviation (SD) or standard error, or median with interquartile range and categorical data are presented as frequency counts (%). For serum levels of sFlt-1, PlGF and the sFlt-1/PlGF ratio, statistical testing was conducted after logarithmic transformation, because in our previous studies using serum levels of sFlt-1, PlGF and the sFlt-1/PlGF ratio, the data showed almost normal distributions after logarithmic transformation. 17 However, the data of serum levels of sFlt-1, PlGF and the sFlt-1/PlGF ratio were presented using the absolute values instead of logarithmic values. The one-sample t-test was used to compare the data from the woman with AFLP and those in the 14 women with HELLP syndrome. Correlation coefficients among variables were calculated using Spearman correlation. IBM SPSS Statistics (version 21 for Windows) were used for the analysis. P value less than 0.05 was considered significant.
Results
Four patients, who were all complicated in preeclampsia during pregnancy period and delivered their babies at 32 +1 , 36 +3 , 37 +1 and 38 +6 weeks of gestation, occurred HELLP syndrome in the puerperal period, whereas 10 patients developed HELLP syndrome during pregnancy period (Table 1) . HELLP syndrome occurred at a median of 32.6 weeks of gestation in 10 women in whom HELLP syndrome occurred in pregnancy period. Half of the women with HELLP syndrome were nulliparous. Fetuses were delivered at a median of 33.4 weeks of gestation. A total of 36% of HELLP syndrome patients delivered SGA infants.
Case report of a women with AFLP
A 33-year-old nulliparous woman developed vomiting with slight hematemesis at 36 +3 weeks of gestation, the symptom continued and she noticed blackened stools. She had a past history of gastric ulcer at 23 years old; although she had been prescribed a proton pump inhibitor, she had discontinued taking the medicine because her pain had disappeared; thereafter, the gastric ulcer had not recurred. Then, she visited a clinic at 37 +1 weeks of gestation, revealing that her fetus had died in utero. Blood examination revealed that she had severe anemia with a hemoglobin value of 6.6 g/dL. Therefore, she was transferred to our hospital on the same day. The blood pressure was 165/101 mmHg, but proteinuria was negative. She did not show any signs of placental abruption. The main laboratory findings on admission were as follows: white blood cell (WBC) count, 21 500/μL; hemoglobin, 5.6 g/dL with a mean cell volume of 85 fL; platelet count, 17.7 × 10 4 /μL; AT activity, 30.8%; AST, 523 U/L; ALT, 492 U/L; LDH, 1282 U/L; total bilirubin, 2.31 mg/dL; uric acid, 16.2 mg/dL; creatinine, 1.88 mg/dL; blood sugar, 115 mg/dL; fibrin degradation products, 12.2 μg/mL; D-dimer, 2.2 μg/mL; and fibrinogen, 187 mg/dL. Because vomiting, elevated bilirubin, elevated urate, leukocytosis, elevated transaminases and renal impairment were observed on admission, we diagnosed her with AFLP. A male infant weighing 2800 g was transabdominally delivered on the same day. Eight units of red blood cells and 1500 units of AT preparation were administered during the operation. The blood pressure levels increased to 200/110 mmHg soon after the operation, and then nicardipine was administered intravenously. AT activity 3 days after the operation was 32.3% and 1500 units of AT were administered; however, the AT activity 5 days after the operation was around 60% despite two AT preparation replacements; thereafter, the activity recovered, and reached 90%. The platelet count decreased to 8.3 × 10 4 /μL a day after the operation, the low platelet count of <10 × 10 4 /μL continued until 4 days after the operation; then, the platelet count increased 5 days after the operation. The AST/ALT levels were high until 10 days after the operation; and the AT activity, platelet count and AST/ALT levels were normalized 11 days after the operation.
Because she developed hematemesis on the second night after the operation, a proton pump inhibitor (omeprazole: 20 mg twice a day) was started intravenously and she underwent esophagogastroduodenoscopy 2 days after the operation, resulting in the diagnosis of a duodenal ulcer with active bleeding. Endoscopic clipping was performed to stop the Small-for-gestational-age infant (%) 5 (36) 0 0 †The mean gestational weeks of the onset of HELLP syndrome were calculated using 10 cases of HELLP syndrome which occurred in pregnancy period. However, the blood samplings of all 14 patients with HELLP syndrome were performed during pregnancy period.; ‡Four women with HELLP syndrome which occurred in the puerperal period delivered their babies at 32 +1 , 36
+3
, 37
+1 and 38 +6 weeks of gestation. ALT, alanine aminotransferase; AST, aspartate aminotransferase; AT, antithrombin; BMI, body mass index; CRP, C-reactive protein; DBP, diastolic blood pressure; GH, gestational hypertension; LDH, lactate dehydrogenase; PE, pre-eclampsia; SBP, systolic blood pressure; WBC, white blood cells. bleeding at the same time. A volume of 60 mL/day of 5% sodium alginate was prescribed 2 days after the operation for 14 days; 30 mg/day of lansoprazole was prescribed 8 days after the operation, followed by 20 mg/day of esomeprazole 11 days after the operation, because tarry stools continued, suggesting the continuation of low-level bleeding from the duodenal ulcer; then, the tarry stools disappeared. Since she was positive for anti-Helicobacter pylori IgG antibody, H. pylori eradication was started, and it was completely eradicated. Esophagogastroduodenoscopy 5 months after the initiation of H. pylori eradication revealed that the ulcer had completely healed.
Comparison of serum levels of sFlt-1, PlGF and the sFlt-1/PlGF ratio between 14 women with HELLP syndrome and a woman with AFLP, using onesample t-test.
The mean (−SD to +SD) of the serum level of sFlt-1 in women with HELLP syndrome was 15 500 (7900-30 200) pg/mL. The serum level of Flt-1 in the woman with AFLP, 273040 pg/mL, was markedly higher than in those with HELLP syndrome (P < 0.001) (Fig. 1a) . The serum level of sFlt-1/PlGF in the woman with AFLP was also markedly higher than the mean serum level of sFlt-1/PlGF in women with HELLP syndrome (4236 vs 234 [95-574], respectively, P < 0.001) (Fig. 1c) . However, the serum level of PlGF in the woman with AFLP was not significantly different from the mean serum level of PlGF in women with HELLP syndrome (64 vs 66 [35-122], respectively, P = 0.877) (Fig. 1b) .
The frequencies of high sFlt-1, low PlGF and a high sFlt-1/PlGF ratio in the woman with AFLP and women with HELLP syndrome were not significantly different ( Table 2 ). The woman with AFLP showed high sFlt-1, low PlGF and a high sFlt-1/PlGF ratio. Women with HELLP syndrome showed high sFlt-1 (93%), low PlGF (86%) and a high sFlt-1/PlGF ratio (86%).
Spearman correlation coefficients among serum levels of sFlt-1, PlGF, the sFlt-1/PlGF ratio, maximum systolic blood pressure (SBP), maximum diastolic blood pressure (DBP), WBC at onset, Creactive protein (CRP) at onset, maximum AST, maximum ALT, maximum LDH, nadir platelet count and nadir AT activity in 14 women with HELLP syndrome and a woman with AFLP. Serum levels of sFlt-1, PlGF and the sFlt-1/PlGF were significantly correlated with maximum SBP and maximum DBP in 14 women with HELLP syndrome and a woman with AFLP (Table 3) . Serum levels of sFlt-1 and the sFlt-1/PlGF ratio were significantly correlated with AST and ALT; and serum level of PlGF was significantly inversely correlated with platelet count and AT activity. WBC at sampling was significantly correlated with SBP.
Discussion
Serum levels of sFlt-1 and the sFlt-1/PlGF ratio, but not PlGF, in a woman with AFLP were markedly higher than those in women with HELLP syndrome. AFLP may be a different clinical entity from HELLP syndrome based on angiogenesis-related factors. In addition, the sFlt-1/PlGF ratio may be clinically useful to rapidly distinguish AFLP from HELLP syndrome. 1 (100) 12 (86) 1.000 †Ten patients developed HELLP syndrome in pregnancy period, whereas four patients developed HELLP syndrome in the puerperal period. However, the blood samplings of all 14 cases of HELLP syndrome were performed during pregnancy period. Table 3 Spearman correlation coefficients among serum levels of soluble fms-like tyrosine kinase 1 (sFlt-1), placental growth factor (PlGF), the sFlt-1/PlGF ratio, maximum systolic blood pressure (SBP), maximum diastolic blood pressure (DBP), white blood cells (WBC) at onset, C-reactive protein (CRP) at onset, maximum aspartate aminotransferase (AST), maximum alanine aminotransferase (ALT), maximum lactate dehydrogenase (LDH), nadir platelet count and nadir antithrombin (AT) activity in 14 women with hemolysis, elevated liver enzymes and low platelet count syndrome and a woman with acute fatty liver of pregnancy † 
1.000
*P < 0.05; **P < 0.01; ***P < 0.001. †Bold fonts indicate significant correlation.
AFLP may be a different disease from HELLP syndrome from the perspective of angiogenesis-related factors, because serum levels of sFlt-1 and the sFlt-1/ PlGF ratio, but not PlGF, in the woman with AFLP were markedly higher than those in women with HELLP syndrome. The level of sFlt-1 and sFlt-1/PlGF ratio in the woman with AFLP was 18 (=275 423 Ä 15 488) and 18 (=4266 Ä 234) times higher than the mean level of sFlt-1 and sFlt-1/PlGF ratio in women with HELLP syndrome, respectively. We did not encounter pregnant women with a serum level of sFlt-1 greater than 100 000 pg/mL using the ECLIA method, including normal and pre-eclamptic women. 17 In women with HELLP syndrome, the levels of sFlt-1 were all less than 100 000 pg/mL. Because the abnormality of sFlt-1 levels in pregnancy is related to endothelial dysfunction in preeclampsia, 19, 20 the markedly increased levels of sFlt-1 in our AFLP patient might have reflected severer endothelial dysfunction underlying this condition, and thereby might have been associated with the genesis of liver dysfunction, renal dysfunction, low AT activity and thrombocytopenia, and also associated with the slow amelioration of all these abnormalities.
A duodenal ulcer with active bleeding may be a novel complication of AFLP. Our case of AFLP showed six features in the Swansea criteria: vomiting, elevated bilirubin, elevated urate, leukocytosis, elevated transaminases and renal impairment. However, the Swansea criteria do not include gastrointestinal features. Although the cause-effect relationship between the occurrence of duodenal ulcer with active bleeding and the occurrence of AFLP is unknown, markedly increased sFlt-1 might lead to duodenal injuries followed by ulcer formation in pregnant women. To the best of our knowledge, this is the first case report of a duodenal ulcer with active bleeding at the occurrence of AFLP. The present patient had a past history of a gastric ulcer, and psychological/physical stress sometimes deteriorates peptic ulcers: she was severely ill, which was a stressful condition. Thus, we cannot state that the duodenal ulcer was solely due to AFLP. However, as AFLP is defined mainly based on symptoms/laboratory data and as duodenal ulcer bleeding markedly affected the patient's condition, we believe that a duodenal ulcer may be an important AFLP manifestation, and, thus, a possible new feature of AFLP. The following may support this view. First, bevacizumab, a blocker of Flt-1 with a similar function to sFlt-1, can induce bowel perforation, [21] [22] [23] suggesting that markedly increased sFlt-1 might have led to duodenal injuries followed by ulcer formation in this patient. Second, a previous report described a woman with post-partum duodenal perforation after AFLP 24 : duodenal ulcer and duodenal perforation are not the same conditions but they show marked similarities in pathophysiology.
Why our AFLP patient showed markedly high level of sFlt-1? Although we do not completely explain the reasons why the serum level of sFlt-1 was markedly increased in our patient, we speculate that the complication of gestational hypertension in this patient might be implicated in the increase of sFlt-1, because there are some women with gestational hypertension in whom the circulating level of sFlt-1 is increased to the almost same level in women with pre-eclampsia. 25 However, it is difficult to explain the reason why serum sFlt-1 level in AFLP patients was higher than that of HELLP syndrome patients in view of the complication of gestational hypertension. Because our case of AFLP showed leukocytosis, markedly decrease of AT activity and acute kidney injury, she might have been complicated with severe endothelial dysfunction. AFLP relates severe inflammation. Severe inflammation may lead to increased sFlt-1 levels and result in endothelial injury. For example, the aggravated inflammation results in high sFLt-1 levels in the acute pancreatitis patients. 26 Therefore, we speculate that the markedly increased level of sFlt-1 might have affected the generation of endothelial dysfunction and multiorgan failure.
This study has a limitation because markedly higher levels of sFlt-1 and the sFlt-1/PlGF ratio in a case of AFLP has not been validated by further cases of AFLP. Therefore, our hypothesis that sFlt-1 and the sFlt-1/PlGF ratio in AFLP patients are higher than those in HELLP syndrome patients should be evaluated by accumulating AFLP cases and measuring circulating levels of angiogenesis-related factors.
In conclusion, serum levels of sFlt-1 and the sFlt-1/ PlGF ratio, but not PlGF, in a woman with AFLP were markedly higher than those in women with HELLP syndrome, suggesting that AFLP may be a different clinical entity from HELLP syndrome based on angiogenesis-related factors. Clinically, the sFlt-1/ PlGF ratio may be used to rapidly distinguish AFLP from HELLP syndrome. 1 and PlGF. This work was supported by the Grantsin-Aid (17K11247 to A. O., and S1311029 to S. M.) from the Ministry of Education, Culture, Sports, Science and Technology, Japan.
